How we manage patients with pyruvate kinase deficiency

Rachael F. Grace, D. Mark Layton, Wilma Barcellini

Research output: Contribution to journalReview article

Abstract

Novel therapies in development have brought a new focus on pyruvate kinase deficiency (PKD), the most common congenital haemolytic anaemia due to a glycolytic enzyme deficiency. With an improved recognition of its clinical presentation and understanding of the diagnostic pathway, more patients are likely to be identified with this anaemia. Complications, including gallstones and non-transfusion-related iron overload, require monitoring for early diagnosis and management. Current management remains supportive with red cell transfusions, chelation and splenectomy. Decisions to transfuse and/or splenectomise must be individualised. Haematopoietic stem cell transplant has been pursued in a small number of patients with mixed outcomes. Novel treatment approaches, which range from a small molecule pyruvate kinase activator to gene therapy, may transform the way in which PKD is managed in the future. In this review, we discuss the pathophysiology of PKD and present our approaches to diagnosis, monitoring and management of patients with this anaemia.

Original languageEnglish
Pages (from-to)721-734
Number of pages14
JournalBritish Journal of Haematology
Volume184
Issue number5
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Anemia
Congenital Hemolytic Anemia
Pyruvate Kinase
Iron Overload
Physiologic Monitoring
Gallstones
Splenectomy
Hematopoietic Stem Cells
Genetic Therapy
Early Diagnosis
Transplants
Enzymes
Therapeutics
Pyruvate Kinase Deficiency of Red Cells

Keywords

  • congenital haemolytic anaemia
  • iron overload
  • Pyruvate kinase deficiency
  • splenectomy
  • transfusions

ASJC Scopus subject areas

  • Hematology

Cite this

How we manage patients with pyruvate kinase deficiency. / Grace, Rachael F.; Mark Layton, D.; Barcellini, Wilma.

In: British Journal of Haematology, Vol. 184, No. 5, 01.03.2019, p. 721-734.

Research output: Contribution to journalReview article

Grace, Rachael F. ; Mark Layton, D. ; Barcellini, Wilma. / How we manage patients with pyruvate kinase deficiency. In: British Journal of Haematology. 2019 ; Vol. 184, No. 5. pp. 721-734.
@article{a2516cdaa9ab48be8b8cd800cef6fba6,
title = "How we manage patients with pyruvate kinase deficiency",
abstract = "Novel therapies in development have brought a new focus on pyruvate kinase deficiency (PKD), the most common congenital haemolytic anaemia due to a glycolytic enzyme deficiency. With an improved recognition of its clinical presentation and understanding of the diagnostic pathway, more patients are likely to be identified with this anaemia. Complications, including gallstones and non-transfusion-related iron overload, require monitoring for early diagnosis and management. Current management remains supportive with red cell transfusions, chelation and splenectomy. Decisions to transfuse and/or splenectomise must be individualised. Haematopoietic stem cell transplant has been pursued in a small number of patients with mixed outcomes. Novel treatment approaches, which range from a small molecule pyruvate kinase activator to gene therapy, may transform the way in which PKD is managed in the future. In this review, we discuss the pathophysiology of PKD and present our approaches to diagnosis, monitoring and management of patients with this anaemia.",
keywords = "congenital haemolytic anaemia, iron overload, Pyruvate kinase deficiency, splenectomy, transfusions",
author = "Grace, {Rachael F.} and {Mark Layton}, D. and Wilma Barcellini",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/bjh.15758",
language = "English",
volume = "184",
pages = "721--734",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - How we manage patients with pyruvate kinase deficiency

AU - Grace, Rachael F.

AU - Mark Layton, D.

AU - Barcellini, Wilma

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Novel therapies in development have brought a new focus on pyruvate kinase deficiency (PKD), the most common congenital haemolytic anaemia due to a glycolytic enzyme deficiency. With an improved recognition of its clinical presentation and understanding of the diagnostic pathway, more patients are likely to be identified with this anaemia. Complications, including gallstones and non-transfusion-related iron overload, require monitoring for early diagnosis and management. Current management remains supportive with red cell transfusions, chelation and splenectomy. Decisions to transfuse and/or splenectomise must be individualised. Haematopoietic stem cell transplant has been pursued in a small number of patients with mixed outcomes. Novel treatment approaches, which range from a small molecule pyruvate kinase activator to gene therapy, may transform the way in which PKD is managed in the future. In this review, we discuss the pathophysiology of PKD and present our approaches to diagnosis, monitoring and management of patients with this anaemia.

AB - Novel therapies in development have brought a new focus on pyruvate kinase deficiency (PKD), the most common congenital haemolytic anaemia due to a glycolytic enzyme deficiency. With an improved recognition of its clinical presentation and understanding of the diagnostic pathway, more patients are likely to be identified with this anaemia. Complications, including gallstones and non-transfusion-related iron overload, require monitoring for early diagnosis and management. Current management remains supportive with red cell transfusions, chelation and splenectomy. Decisions to transfuse and/or splenectomise must be individualised. Haematopoietic stem cell transplant has been pursued in a small number of patients with mixed outcomes. Novel treatment approaches, which range from a small molecule pyruvate kinase activator to gene therapy, may transform the way in which PKD is managed in the future. In this review, we discuss the pathophysiology of PKD and present our approaches to diagnosis, monitoring and management of patients with this anaemia.

KW - congenital haemolytic anaemia

KW - iron overload

KW - Pyruvate kinase deficiency

KW - splenectomy

KW - transfusions

UR - http://www.scopus.com/inward/record.url?scp=85060598339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060598339&partnerID=8YFLogxK

U2 - 10.1111/bjh.15758

DO - 10.1111/bjh.15758

M3 - Review article

C2 - 30681718

AN - SCOPUS:85060598339

VL - 184

SP - 721

EP - 734

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -